News

Aug 2018 | eMurmur ID filed for FDA 510(k) and CE regulatory clearance

eMurmur announced today that it has submitted its clinical screening software tool to the US Federal Drug Administration (FDA) as part of an application for FDA 510(k) clearance. This filing is in addition to eMurmur’s application and filing for European CE regulatory clearance which was submitted in June 2018.

Jun 2018 | eMurmur graduates from Creative Destruction Labs

eMurmur announced today that it has successfully graduated from the Creative Destruction Labs (CDL), a highly competitive and successful seed-stage program for massively scalable, science-based companies. eMurmur participated in the 9-month program as part of the CDL-West’s health stream.

May 2018 | Dr. Derek Exner joins eMurmur as a medical advisor

eMurmur announces that renowned cardiologist, Dr. Derek Exner, Professor has joined its advisory board. Dr. Exner is Canada Research Chair, Cardiovascular Clinical Trials; Associate Dean, Clinical Trials, Cumming School of Medicine; and Professor, Department of Cardiac Sciences and Community Health Sciences, University of Calgary.

Feb 2018 | eMurmur opens North American sales and marketing office in Ottawa, Canada

eMurmur announced today that it has incorporated in Canada and opened an office in Ottawa to address the North America market in order to begin to build out its sales, marketing and market development team. eMurmur will continue to operate and grow its R&D facilities in Graz, Austria.

Nov 2017 | Data from comparative clinical study presented at AHA Scientific Sessions 2017

Dr. Lillian Lai of Children’s Hospital Eastern Ottawa presented a study today titled “Performance Evaluation of Two Heart Murmur Detection Applications by Prospective Clinical Trial” at the AHA Scientific Session 2017 today.
The study included 93 patients and demonstrated a sensitivity and specificity for automated detection of pathologic murmurs of 84.4% and 85.9%, respectively, with the gold standard being echocardiography, with eMurmur significantly outperform the other device.
Read the abstract
Read more on Business Wire

Nov 2017 | Results from Johns Hopkins study presented at AHA Scientific Sessions 2017

In the AHA Scientific Session “Best Abstracts in Health Tech ”, Dr. W. Reid Thompson, associate professor of pediatrics at Johns Hopkins University, today presented a study titled “Validation of a Heart Murmur Algorithm by Virtual Clinical Trial” which used the eMurmur algorithm to blindly analyze 3,180 heart sound recordings from the Johns Hopkins Cardiac Auscultatory Recording Database (CARD). Study results showed a sensitivity of 93% and a specificity of 81%, as well as an accuracy of 88%.
Read the Abstract
Read more on Business Wire

July 2017 – eMurmur’s heart murmur detection algorithm scores 89% sensitivity in an elderly population clinical trial

eMurmur announces completion of a clinical trial evaluating the performance of its heart murmur detection algorithms on an elderly population with congenital heart disease. The algorithm’s sensitivity for autonomous detection of pathologic murmurs was 89%. No high severity cases were missed by the algorithm. Further, it yielded accurate heart rate estimation and S1/S2 detection, despite the presence of significant environmental noise.
Read the abstract

Nov 2016 | eMurmur’s heart murmur detection algorithm scores 94% accuracy in clinical pilot study

eMurmur announces impressive pilot study of its AI platform on 106 children at Children’s Hospital of Eastern Ontario, Canada, where it differentiated pathologic from innocent heart murmurs with high sensitivity (87%) and specificity (100%), a positive predictive value of 100%, a negative predictive value of 90%, and high accuracy (94%) when compared with echocardiography as the gold standard for diagnosing murmurs.
Read more on Business Wire
Read the publication

Oct 2016 | Dr. Andrew Redington joins as a medical advisor

eMurmur announces Andrew Redington, MD, an internationally renowned cardiologist and Chief of Pediatric Cardiology at Cincinnati Children’s Hospital in Ohio, United States, joins the company as a medical adviser.
Read more on Business Wire

May 2016 | Dr. Lillian Lai joins as a medical advisor

eMurmur announces that Lillian Lai, MD, Cardiologist at Children's Hospital of Eastern Ontario, Canada joins the company as a medical advisor. Dr. Lai previously served as a Principal Investigator on several clinical studies for the development and validation of the eMurmur technology.

Feb 2016 | eMurmur recipient of major Austrian government funding

eMurmur approved to receive up to EUR 600,000 in Seed financing from the Austrian government, aimed to help transform well formulated business ideas around innovative technologies into a start-up ready for market entry.

July 2015 | eMurmur awarded prestigious European Horizon 2020 research grant

The European Commission awards a prestigious EUR 50,000 Horizon 2020 grant to eMurmur to advance its R&D into a clinically tested mobile-based technology for the objective detection and classification of heart murmurs.

May 2015 | eMurmur wins Best of Biotech business plan competition

eMurmur wins the special MedTech award at the seventh international business plan competition "Best of Biotech". The competition awards excellence in the areas of life science and medical technology, is organised by Austria Wirtschaftsservice and commissioned by the Austrian Federal Ministry of Science, Research and Economy. A total of 30 projects with economic potential from six countries were selected by an international jury comprised of experts from the fields of industry, finance and economics. eMurmur was awarded a prestigious prize worth EUR 10,000.

Dec 2014 | eMurmur founded in Graz, Austria, and first round of angel investments

CSD Labs GmbH (d.b.a. eMurmur) was formally founded in Graz, Austria with the vision of leveraging state-of-the art signal processing, machine learning, and high quality clinical datasets to create an autonomous heart murmur detection AI. Additionally, eMurmur raises EUR 420,000 from US angel investors.

Jul 2013 | Founders receive prestigious Start-up grant from Austrian government

Founders Andreas Schriefl (PhD Physicist / Biomedical Engineer) and Andreas Reinisch (Computer Science & Biomedical Engineer) receive a prestigious start-up grant of EUR 210,000 from the Austrian government, rewarded to promising high-tech ideas with high-growth potential to allow for preliminary feasibility work on heart sound analysis and development of a business plan around the founders’ vision.

Our Team

 

Andreas Schriefl

> Founder and CEO

 

Andreas Reinisch

> Co-founder and CTO

 

Patrick Walsh

> CFO

 

Chris Grubb

> Director Sales & Market Development

Advisors

 

Andrew Redington, MD

Executive Co-Director, Heart Institute
Chief, Pediatric Cardiology, Cincinnati Children’s Hospital
Professor, UC Dept of Pediatrics

 

Derek Exner, MD

Professor, Department of Cardiac Sciences and Community Health Sciences, University of Calgary. Associate Dean, Clinical Trials, Cumming School of Medicine
Canada Research Chair, Cardiovascular Clinical Trials

 

Lillian Lai, MD

Cardiologist, CHEO Hospital
Assistant Professor, University of Ottawa

 

Michael Farrell

Business Development Advisor

 

Pat Beirne

Software Engineering Advisor

Partners

partner_logos